Novadoz Pharmaceuticals LLC recalled Glycopyrrolate Oral Solution on December 15, 2025, due to failed impurities and degradation specifications. The recall affects Rx only products manufactured by MSN Pharmaceuticals Inc. Consumers should stop using this medication immediately.
Failed Impurities/Degradation Specifications
Consumers and healthcare providers should stop using this product immediately. Contact NOVADOZ PHARMACEUTICALS LLC or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled Glycopyrrolate Oral Solution has the NDC 72205-070-72. It comes in a 16 oz. (473 mL) bottle. Specific lot numbers include CB2505159A, CB2505160A, and CB2505161A, with expiration dates of April 2027 and May 2027.
The product failed impurities and degradation specifications, which could compromise its safety and efficacy. This poses a considerable risk to consumers, especially those relying on this medication for health management.
There are currently no reported injuries or incidents associated with this recall. However, the potential for health risks remains high due to the nature of the impurities.
Stop using the Glycopyrrolate Oral Solution immediately. Contact Novadoz Pharmaceuticals LLC or your healthcare provider for further guidance.
For more information, call Novadoz Pharmaceuticals LLC or visit their website. Details can also be found on the FDA's recall page.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.